PDCD1 and neoplasm: Since patients with MSI-H express many tumor-specific antigens due to the high mutation burden caused by dMMR, this triggers an immune response mediated by cytotoxic T cells, whose effector phase is downregulated by the recognition of PD-1 on T cells and PD-L1 on tumor cells.